Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 Pazdur, 2004 2007 Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 2007 Sandler, 2006, Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022 Reck, 2010, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL, J Clin Oncol, 27, 2415 Ciardiello, 2000, Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells, Clin Cancer Res, 6, 3739 Shaheen, 2001, Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors, Br J Cancer, 85, 584, 10.1054/bjoc.2001.1936 Bozec, 2008, Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model, Br J Cancer, 99, 93, 10.1038/sj.bjc.6604429 Schicher, 2009, Erlotinib and bevacizumab have synergistic activity against melanoma, Clin Cancer Res, 15, 3495, 10.1158/1078-0432.CCR-08-2407 Wu, 2007, Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade, Mol Cancer Ther, 6, 471, 10.1158/1535-7163.MCT-06-0416 Herbst, 2005, J Clin Oncol, 23, 2544, 10.1200/JCO.2005.02.477 Herbst, 2007, Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer, J Clin Oncol, 25, 4743, 10.1200/JCO.2007.12.3026 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Dmitrienko, 2005 Westfall, 2001, Optimally weighted, fixed sequence and gatekeeper multiple testing procedures, J Stat Planning Inference, 99, 25, 10.1016/S0378-3758(01)00077-5 Brookmeyer, 1982, A confidence interval for median survival time, Biometrics, 38, 29, 10.2307/2530286 Ciardiello, 2004, Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy, Clin Cancer Res, 10, 784, 10.1158/1078-0432.CCR-1100-03 Naumov, 2009, Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance, Clin Cancer Res, 15, 3484, 10.1158/1078-0432.CCR-08-2904 Herbst, 2010, Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial, Lancet Oncol, 11, 619, 10.1016/S1470-2045(10)70132-7 Natale, 2009, Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study, J Clin Oncol, 27, 2523, 10.1200/JCO.2008.18.6015 Hirsch, 2008, Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer, Clin Cancer Res, 14, 6317, 10.1158/1078-0432.CCR-08-0539 Andratschke, 2004, Epidermal growth factor receptor as a target to improve treatment of lung cancer, Clin Lung Cancer, 5, 340, 10.3816/CLC.2004.n.012 Roskoski, 2004, The ErbB/HER receptor protein-tyrosine kinases and cancer, Biochem Biophys Res Commun, 319, 1, 10.1016/j.bbrc.2004.04.150 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Pao, 2004, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci USA, 101, 13306, 10.1073/pnas.0405220101 Eberhard, 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib, J Clin Oncol, 23, 5900, 10.1200/JCO.2005.02.857 Miller, 2008, Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib, J Clin Oncol, 26, 1472, 10.1200/JCO.2007.13.0062 Miller, 2009, Proc Am Soc Clin Oncol, 27, LBA8002, 10.1200/jco.2009.27.18_suppl.lba8002